对于卵巢癌的CAR-T和CAR-NK细胞疗法的当前发展
Alireza Azani1, Sahar Hasani2, Malihe Sharafi1
1Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Stem cell reviews and reports
|December 27, 2025
概括
化学抗原受体 (CAR) -T和CAR-自然杀手 (NK) 细胞疗法在治疗卵巢癌 (OC) 方面表现有前途. 虽然CAR-T疗法在固体瘤中面临挑战,但CAR-NK细胞为OC免疫疗法提供了潜在的更安全,更有效的方法.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
背景情况:
- 卵巢癌 (OC) 是一种致命的妇科恶性瘤,由于晚期诊断,异质性和化学抵抗性,其存活率较低.
- 目前对OC的治疗有局限性,需要新的治疗策略.
研究的目的:
- 审查化学抗原受体 (CAR) -T和CAR-自然杀手 (NK) 细胞疗法在卵巢癌治疗中的潜力.
- 检查关键的瘤相关抗原和基于CAR的治疗OC的挑战.
主要方法:
- 关于卵巢癌中CAR-T和CAR-NK细胞疗法的现有文献的全面审查.
- 对临床前研究和早期临床试验的分析,重点关注特定抗原和治疗方法.
主要成果:
- 卡尔-T和卡尔-NK细胞向FRα,MSLN,HER2,EpCAM,MUC16,Tn-glycopeptide,TAG-72和OC中过度表达的LGR5等抗原.
- 卡尔-T细胞表现出细胞毒性,但在固体瘤中面临挑战;卡尔-NK细胞提供了潜在的优势,如降低毒性和现成的可用性.
- 正在探索组合策略和创新方法,如CRISPR编辑.
结论:
- 基于CAR的免疫疗法,特别是CAR-NK细胞,是治疗卵巢癌的有希望的途径.
- 进一步的研究和临床试验对于确定CAR-T和CAR-NK细胞疗法的疗效和优化在OC中的应用至关重要.
更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
1.7K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.2K
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K